Generation of Human Epidermis-Derived Mesenchymal Stem Cell-like Pluripotent Cells (hEMSCPCs)

Bing Huang1, Kaijing Li1, Jie Yu1, Min Zhang1, Yongping Li1, Weihua Li1, Wencong Wang1, Liping Guan1, Wenxin Zhang1, Shaochun Lin1, Xintao Huang1, Liping Lin1, Yongliang Lin1, Yichi Zhang1, Xinming Song2, Zhichong Wang1 & Jian Ge1

1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, GuangZhou 510060, China, 2Genetic Laboratory of Sun Yat-sen University, GuangZhou 510080, China.

We isolated human epidermis-derived mesenchymal stem cell-like pluripotent cells (hEMSCPCs) and demonstrate efficient harvesting, maintenance in vitro for at least 30 passages, reprogramming into multiple phenotypes in vivo, and integration into adult host tissues after injection into the mouse blastocyst to create chimeras. Cell phenotype was examined by karyotyping, immunostaining, immunofluorescence, and flow cytometry. A nested PCR protocol using primers specific for human SRY genes was designed to detect hEMSCPC-derived cells in female chimeric mice. FISH was used to validate the results of nested PCR. Results indicated that hEMSCPCs were derived from epidermis but were distinct from epidermal cells; they resembled mesenchymal stem cells (MSCs) morphologically and expressed the main markers of MSCs. About half of all female offspring of mice implanted with embryos injected with hEMSCPCs at the blastocyst stage harbored the human Y chromosome and tissue-specific human protein, thereby demonstrating the transdifferentiation of hEMSCPCs.

STem cells can be derived from the embryo (embryonic stem cells, ESCs), from adult tissues (adult stem cells, ASCs), and by induction of fibroblasts (induced pluripotent stem cells, iPSCs). However, ethical problems, immunological rejection, and difficulties in obtaining human tissues limit the use of ESCs in clinical medicine1,2, while iPSCs are difficult to maintain in vitro and carry a greater risk of tumor formation. The maintenance and propagation of these cells is especially difficult in the clinic due to the complex harvesting, isolation, and culture conditions required3–10. In contrast, ASCs can be isolated from several adult tissues and present the possibility of self-transplantation for the clinical treatment of a variety of human diseases.

Recently, several ASCs have been successfully isolated and cultured in vitro, including hematopoietic stem cells (HSCs)11, mesenchymal stem cells (MSCs)12,13, epidermis stem cells14, neural stem cells (NSCs)15, adipose-derived stem cells (ADSCs)16–18, islet stem cells19,20, and germ line stem cells21–25. Human mesenchymal stem cells originate mainly from bone marrow26–28, cord blood29–31, placenta29–31, and endometrium32, but epidermis-derived MSCs have not yet been isolated. In the present study, we isolated small spindle-shaped cells with strong proliferative potential from human epidermis. They resembled MSCs morphologically and demonstrated pluripotency in vivo; thus, we defined these cells as human epidermis-derived mesenchymal stem cell-like pluripotent cells (hEMSCPCs). These hEMSCPCs expressed many typical markers of MSCs and NSCs, demonstrated good bio-safety33, and could differentiate into neural-like cells34 and immunocyte-like cells35 under appropriate conditions. In the current study, we demonstrate that hEMSCPCs can be reprogrammed after injection into the mouse blastocyst cavity to form heterogeneous chimeras. Indeed, hEMSCPC-derived cells were present in several organs of the postnatal (1–5-month-old) mouse and expressed organ-specific functional proteins. Consequently, we have not only successfully isolated and cultured a new type of ASC with strong viability in vitro, but also demonstrated reprogramming and transdifferentiation after blastocyst cavity injection. These hEMSCPCs fulfill many of the requirements for clinical cell therapy, including large-scale harvesting, prolonged expansion in vitro, biocompatibility and safety, and pluripotency.

Results
Derivation of hEMSCPCs and morphology in vitro. To obtain human epidermis-derived mesenchymal stem cell-like pluripotent cells (hEMSCPCs), we first designed a selective culture medium (hEMSCPC-specific
medium). We obtained eight foreskin specimens from surgical patients confirmed negative for HIV, hepacivirus, and leptospira infection. After treating the foreskin tissue with a digestive solution, the tissue was washed at least five times in PBS to prevent hypodermal cell contamination, and the epithelial layer isolated from the basilar membrane and treated with a digestive solution. Individual epithelial cells were then obtained by mechanical trituration, resuspended in hEMSCPC-specific medium, and cultured. On day two, the culture medium was replaced and non-adherent cells removed. Spindle-shaped cells with small cell bodies were observed after 7–10 days in vitro (P0 7d; Fig. 1A). While the majority of cells died, polygonal epithelial-like cells grew in some cultures. Between days 5 and 10, the culture medium was replaced (as indicated by acidification) with gentle agitation to remove dead cells. The number of spindle-shaped cells with small cell bodies gradually increased over the next days and weeks (Fig. 1A, P0 12d & P0 15d). These spindle-shaped cells were harvested at two to three weeks in vitro as they were more easily detached from the culture plates than the polygonal epithelial-like cells. Thus, we could selectively separate these two cell types by controlling the digestion time.

Isolated spindle-shaped cells with small cell bodies were then cultured alone in hEMSCPC-specific medium. Cells were split at 1:3 every 1.5–3 days (Fig. 1B, P2 2d) and they continued to proliferate rapidly up to passage 30. Most of these cells were short and spindle-shaped before passage 10 (Fig 1B, P2 2d), but showed greater morphological heterogeneity after passage 10 (Fig. 1C–E). Most had two to three projections (Fig. 1C, round figure on the left, indicated by the arrow), while a few had several projections (Fig. 1C, round figure on the right, indicated by the arrow). In some specimens, most of the hEMSCPCs had short projections and only a few had longer slender projections (Fig. 1D, round figure on the left, indicated by the arrow), while hEMSCPCs obtained from other specimens had mostly long slender projections. When hEMSCPCs formed a monolayer, they took on a vortex pattern resembling MSCs (Fig. 1F). Karyotyping between passages 30 to 32 revealed 46 chromosomes with X and Y (Supplementary Fig. 1).

**Marker protein expression patterns revealed by immunocytochemistry.** Past studies have not found mesenchymal stem cells in the epidermis, so the origin of these hEMSCPCs cells was initially uncertain. We surmised that epidermal stem cells might transdifferentiate into hEMSCPCs in the microenvironment supplied by the special medium. To investigate this possibility and to examine phenotypic changes during long-term culture, we examined the expression of several markers known to be expressed by skin-derived cells, including the MSC markers CD73, CD90, and CD105, the fibroblast marker vimentin, the NSC marker nestin, the neuronal marker β-III tubulin, the glial marker GFAP, the immunocyte markers CD3, CD19, CD16, and CD45, the HSC marker CD34, the epithelial cell marker CK19, the basilar membrane cell marker CD10, the vascular endothelial cell markers CD31 and VEGF-R2, and the human histocompatibility antigens HLA-DR and HLA-I. We assessed expression patterns at passages 2, 10, 20, and 30 by immunohistochemistry. Only a fraction of hEMSCPCs expressed CD90 and nestin (Fig. 2A) at passage 2, but almost all expressed CD90 (Fig. 2I) and nestin (Fig. 2C) at passages 10, 20, and 30. At all passages, most hEMSCPCs expressed CD73 (Fig. 2I) and vimentin (Fig. 2B, D), while a significant fraction expressed CD105 (Fig. 2K), and a few cells expressed β-III tubulin, GFAP, CK19 (Fig. 2E), or CD10 (Fig. 2F). Very few expressed the immunocyte markers CD3 (Fig. 2G), CD19, CD16, or CD45, or the HSC marker CD34. No cells at passage 2 expressed the vascular endothelial cells markers CD31.
and VEGF-R2 (Fig. 2H), while only a few CD31 and VEGF-R2 positive cells were found at passages 10, 20, and 30. Some hEMSCPCs were positive for human histocompatibility antigens HLA-DR and HLA-I at passage 2 (Fig. 2M), but expression decreased with passage and time in culture. Some cultures showed no HLA-DR-positive cells at passages 10, 20, or 30 (Fig. 2L).

**Quantitative analysis of marker protein expression changes by flow cytometry.** For quantitative analysis, we detected marker expression at passages 2, 10, 20, and 30 by flow cytometry. The results confirmed immunohistochemistry results. Cultured hEMSCPCs expressed abundant CD73 and vimentin, moderate CD105, low levels of β-III tubulin, GFAP and CD10, while only sporadic cells expressed CD3, CD19, CD16, CD45, CD34, CD31, VEGF-R2, or CK19 at passages 2, 10, 20, and 30. Cultured hEMSCPCs expressed moderate CD90 and nestin at passage 2, but highly expressed CD90 and nestin at passage 10, 20, and 30. Expression of the human histocompatibility antigens HLA-DR and HLA-I was moderate to low at passage 2, but HLA-positive cells became scarce as the passage number increased. Indeed, no HLA-DR expression was observed in some specimens at passages 10, 20, or 30 (Fig. 2L).

A few CK19-positive hEMSCPCs were detected by immunohistochemistry, but no CK19-positive cell were detected by flow cytometry, possibly because these are epithelial-like cells that cannot be easily detached from the culture flask by trypsin, and so are lost before flow cytometry analysis.

**Construction of chimeras and multipotency of hEMSCPCs.** To determine if these hEMSCPCs were multipotent like other ACSs, we injected these cells into the blastocyst cavities of mouse embryos and followed the development of chimeric mice. As hEMSCPCs expressed only very low levels of the human histocompatibility antigens HLA-DR and HLA-I, we surmised that mouse blastocyst cavity injection would be a viable strategy to study the multipotency of these cells. We injected passage 10–13 hEMSCPCs into the blastocyst cavity, and cultured the embryos in vitro for 13 to 15 hours. Well-developed embryos were transplanted into the uteruses of pseudopregnant female mice and allowed to develop to term. We obtained 135 offspring (73 male and 62 female) that grew without obvious health defects over 1–5 months. We designed two primer pairs specific for human SRY genes of the Y chromosome and used them to detect the human Y chromosomes in blood, brain, heart, lung, spleen, liver and kidney of female mouse offspring by nested PCR. Furthermore, to validate the detection by nested PCR, we performed fluorescence in situ hybridization (FISH) using specific probes for the human Y chromosome and examined immunofluorescence staining for specific markers of human blood, brain, heart, lung, spleen, liver, and kidney cells under confocal laser scanning microscopy.

Results of the nested PCR showed that 27 of 62 female offspring were positive (43.5%) for SRY genes. The distribution of positive organs (Supplementary Table 2) revealed that 15 of 62 (24.2%) female offspring had blood cells positive for SRY genes (Fig. 4A), 4 of 62 (6.5%) had SRY-positive brain tissue (Fig. 4B left), 6 of 62 (9.7%) SRY-positive heart tissue (Fig. 4B right), 4 of 62 (6.5%) SRY-positive kidney tissue (Fig. 4C left), 4 of 62 (6.5%) SRY-positive spleen tissue (Fig. 4C right), 8 of 62 (12.9%) SRY-positive lung tissue (Fig. 4E left), and 3 of 62 (4.8%) SRY-positive liver tissue (Fig. 4E right).

**Figure 2 | Immunohistochemical expression patterns of hEMSCPCs over 30 passages.** (A): Some cells at P2 showed nestin positive immunoreactivity (brown color). (B): Almost all cells at P2 were vimentin positive (brown color). (C): Almost all cells at P10, P20, and P30 showed nestin immunoreactivity (brown color). (D): Almost all cells at P10, P20, and P30 were vimentin immunoreactive (brown color). (E): At P2, P10, P20, and P30, a small number of cells were CK19 immunoreactive (brown color). (F): At P2, P10, P20, and P30, a limited number of CD10 immunoreactive cells were observed (brown color). (G): At P2, P10, P20, and P30, a few individual cells were CD3 immunoreactive (brown color). (H): At P2, no CD31-positive or VEGF R2-positive cells were seen. (I): At P10, P20, and P30, almost all cells expressed CD90 (green fluorescence). (J): At P2, P10, P20, and P30, most cells expressed CD73 (green fluorescence). (K): At P2, P10, P20, and P30, a fraction of cells expressed CD105 (green fluorescence). (L): At P10, P20, and P30, some specimens had no HLA-DR-positive cells. (M): At P10, P20, and P30, a small number of HLA-I-positive cells were observed in some specimens (green fluorescence).
Cultured hEMSCPCs and cells from caudal vein blood of nested PCR-positive mice were analyzed by in situ hybridization, and results confirmed those of nested PCR. Over 90% of the hEMSCPCs were human Y-positive (Fig. 5A), and the positive karyocytes in the caudal vein blood of positive female offspring had differently shaped nuclei (Figure 5 B–E).

We also used human Y-specific probes for in situ hybridization and tissue-specific antibodies for immunofluorescence staining to test for the presence of hEMSCPC-derived cells expressing tissue-appropriate proteins. Indeed, blood, brain, cardiac muscle, lung, spleen, liver, and renal glomerulus cells that were SYR-positive by nested PCR were also positive by in situ hybridization and expressed several tissue-specific human antigens (Supplementary Fig. 2). These antigens included CD3 and CD19 in peripheral blood cells, CD16 in peripheral blood cells and spleen cells, MAP2 and β-III tubulin in brain cells, troponin I in cardiac muscle cells, SP-C and CD31 in lung cells, ALB in liver cells, and VEGF-R2 in renal glomerulus cells. The fraction of cells expressing tissue-specific antibodies was consistent with the fraction expressing the human SRY gene. In 5 randomly chosen human SRY-positive mouse blood samples, 21.821 ± 6.394% of cells were positive for CD3, 14.995 ± 6.178% for CD16, and 17.926 ± 4.528% for CD19 (Supplementary Table 3). In contrast, these specific antigens were undetectable by immunofluorescence staining in cultured hEMSCPCs of the same passage as those injected into the blastocyst cavity (except for a few cells expressing MAP2 and β-III tubulin, results not shown). Thus, hEMSCPCs not only survived in vivo but could reprogram and transdifferentiate into tissue-specific phenotypes. These tissues include ectoderm (brain), mesoderm (blood, heart, spleen and kidney), and endoderm (lung and liver). Therefore, hEMSCPCs are multipotent like all ASCs, can be reprogrammed by the in situ microenvironment of the mouse blastocyst cavity, and have pluripotency to generate all three germ layers.

**Discussion**

Unlike embryonic stem cells (ESCs), neither adult stem cells (ASCs) nor iPSCs can proliferate rapidly in vitro. Furthermore, ASCs and iPSCs cannot be harvested in large quantities and the difficulty of deriving and maintaining these cells makes routine clinical use
unfeasible. While ESC can be harvested and maintained, access is restricted by ethical issues. Thus, there is currently no convenient source of non-embryonic pluripotent stem cells than can be harvested in sufficient quantities and maintained with sufficient ease to satisfy clinical demand and meet the technical requirements for routine hospital maintenance or commercial production. For the current study, we designed a special medium consisting of easily obtainable ingredients and developed isolation and culture methods to obtain human epidermis-derived mesenchymal stem cell-like pluripotent cells (hEMSCPCs) from the adult epithelium of human foreskin. These hEMSCPCs demonstrated strong vitality over multiple passages. On average, we obtained 2.3 x 10^16 cells from a single circumcised foreskin sample. These cells could be stored frozen and then thawed without loss of proliferative capacity. Most importantly, these cells were able to integrate into multiple tissues and express tissue-specific markers. Thus, hEMSCPCs fulfill many of the requirements for clinical cell therapy, including large-scale harvesting, prolonged expansion in vitro, biocompatibility and safety, and pluripotency.

Previous studies have not found mesenchymal stem cell-like cells in the human epidermis, so the question arises as to the origin of these cells. In light of these morphological, immunohistochemical, and flow cytometry results, we suggest that hEMSCPCs are not blood-derived immunocytes or HSCs. These hEMSCPCs did not resemble blood cells morphologically and only sporadic cells expressed hematopoietic stem cell and immunocyte markers. Furthermore, these cells were not vascular endothelial cells (VEC) because they did not express the main VEC markers at passage 2. They were not skin-derived neural cells based on morphological characteristics and the expression of MSC and fibroblast markers. They were not dermis-derived MSCs or fibroblasts as we removed the dermis before culture and strictly controlled for contamination by hypodermal cells by washing the cuticular layers many times with PBS before isolation of the epithelium. In addition, unlike dermis-derived MSCs and fibroblasts, these hEMSCPCs highly expressed the NSC marker nestin and had a tendency to take on a neural cell morphology. In contrast, hEMSCPCs at passages 2, 10, 20, and 30 expressed only low levels of the neuronal marker b-III tubulin and the glial cell marker GFAP. Cuticular layers were isolated during primary cell culture, so we presume that epidermal stem cells in the basilar membrane may transdifferentiate into hEMSCPCs in the microenvironment supplied by the special growth medium. Immunohistochemistry revealed that hEMSCPCs at passages 2, 10, 20, and 30 expressed only low levels of the neuronal marker β-III tubulin and the glial cell marker GFAP. Cuticular layers were isolated during primary cell culture, so we presume that epidermal stem cells in the basilar membrane may transdifferentiate into hEMSCPCs in the microenvironment supplied by the special growth medium. Immunohistochemistry revealed that hEMSCPCs at passages 2, 10, 20, and 30 expressed only low levels of the neuronal marker β-III tubulin and the glial cell marker GFAP. Cuticular layers were isolated during primary cell culture, so we presume that epidermal stem cells in the basilar membrane may transdifferentiate into hEMSCPCs in the microenvironment supplied by the special growth medium. Immunohistochemistry revealed that hEMSCPCs at passages 2, 10, 20, and 30 expressed only low levels of the neuronal marker β-III tubulin and the glial cell marker GFAP. Cuticular layers were isolated during primary cell culture, so we presume that epidermal stem cells in the basilar membrane may transdifferentiate into hEMSCPCs in the microenvironment supplied by the special growth medium. Immunohistochemistry revealed that hEMSCPCs at passages 2, 10, 20, and 30 expressed only low levels of the neuronal marker β-III tubulin and the glial cell marker GFAP. Cuticular layers were isolated during primary cell culture, so we presume that epidermal stem cells in the basilar membrane may transdifferentiate into hEMSCPCs in the microenvironment supplied by the special growth medium. Immunohistochemistry revealed that hEMSCPCs at passages 2, 10, 20, and 30 expressed only low levels of the neuronal marker β-III tubulin and the glial cell marker GFAP.
microenvironment\textsuperscript{41-43}. The special medium selected for development and propagation of hEMSCPCs contains nutrition supplements vital for the growth of mesenchymal stem cells (bFGF and SCF), and indeed the formula is similar to those developed for the culture of mesenchymal stem cells in previous studies\textsuperscript{44-46}. We suggest that epidermal stem cells transdifferentiated into hEMSCPCs under the special microenvironment supplied by this defined medium, although this proposal requires much further study.

Stem cell proliferation and transdifferentiation are dependent on the local microenvironment. In fact, each developmental stage (e.g., embryonic vs. adult) provides a distinct set of microenvironments for implanted stem cell differentiation that are superior to any in vitro culture environment yet developed. When stem cells are injected into the mouse blastocyst cavity, they undergo genetic reprogramming and transdifferentiation. As embryonic development progresses, these stem cells can redistribute and undergo further transdifferentiation under the influence of site-specific microenvironments. Thus, mice blastocyst injection and chimera production is the best tool to determine the multi-directional differentiation potential of stem cells\textsuperscript{47}. We found that hEMSCPCs injected into the mice blastocyst cavity formed heterogeneous chimeras. Implanted cells survived, were reprogrammed, and transdifferentiated into cells of all three germ layers as indicated by the expression of tissue-specific protein markers not detected in hEMSCPCs in vitro (prior to injection). Indeed, hEMSCPC-derived cells were present in several organs of the postnatal (1–5-month-old) mouse and expressed organ-specific functional proteins, suggesting that hEMSCPCs could be used for cell-based therapies. The efficiency of such treatment would depend on the number of hEMSCPCs that survive, transdifferentiate, and integrate into the appropriate target tissue. Further studies must be directed at enhancing survival and quantifying site-specific differentiation of hEMSCPCs using flow cytometry.

In conclusion, we have successfully isolated and cultured a type of mesenchymal stem cell-like pluripotent cell from epidermis with strong proliferative capacity in vitro. Past reports indicated that epidermis does not contain mesenchymal stem cell-like pluripotent cells, so we presume these cells transdifferentiated from epidermal stem cells in the special culture medium, although this conclusion requires additional experimental support.

Methods

Derivation of hEMSCPCs and maintenance in culture. Foreskin tissue was obtained from healthy circumcision patients, soaked in sterile PBS containing 1,000 U/mL gentamycin, and sent to the culture facility within one hour. The tissue was then stored in an 8–10 °C refrigerator for 30 min to 4 hours for subsequent treatment. Tissue was thoroughly rinsed with PBS to remove residual blood and the loose subcutaneous tissue was resected. The tissue was again rinsed at least five times (×5) in PBS to remove blood and tissue debris, and cut into 2 mm-wide strips or 3 mm × 3 mm pieces. These tissue sections were again cleaned with PBS (×5), transferred to sterilized containers (such as 15 mL centrifugation tube), and incubated in 6–8 mL of 2 U/mL dispase II DMEM solution (Gibco, USA) at 6–8 °C for 14–16 hours and then at 36.8 ± 0.2 °C for 1 hour. These partially digested sections were placed onto a sterilized plate and washed with PBS (×5) to remove the remaining tissue debris. The epidermis was separated from the dermis using forceps and placed onto another sterilized plate, rinsed (PBS × 5), cut and crushed, suspended in 10 mL PBS, transferred to 15 mL centrifugation tubes, triturated with glass pipettes, and left to stand for 5–10 min to allow tissue fragments to settle to the bottom. The top fluid layer was removed, the epidermal tissue re-suspended in 10 mL PBS, and again gently pipetted. The tissue was then centrifuged at 1,200 rpm for 5 min and the supernatant discarded. The cell pellet was suspended in 5–6 mL hEMSCPC medium containing 0.25% trypsin, gently pipetted, and incubated at 36.8–37.5 °C for 5–10 min, before media replacement as indicated by media acidification (yellowing). Within 4–5 min after media change the fusiform cells appeared and their number continued to increase thereafter. After 2–3 weeks, a digestion solution containing 0.25% trypsin and 0.02% EDTA (Gibco) in PBS was used for deplating and passage. At this stage, epithelial-like cells were the minority and could be further eliminated at passage because these cells were more adherent than the small fusiform cells. Isolated small fusiform cells were collected and centrifuged for 5 min. The fusiform cell pellet was resuspended in hEMSCPC medium, followed by gentle pipetting. Cells were counted and 5 × 10^5 cells inoculated into new 25 cm\textsuperscript{2} culture flasks for propagation. During the first 30 passages, these fusiform cells grew rapidly, and generally they could be passaged every 1.5–3 days at 1:3. Karyotyping was performed at P30–P32.

Immunocytochemistry. Sterilized 22 mm × 22 mm glass coverslips (thickness 0.13–0.16 mm, CITOCLAS®, China) were placed in 35 mm plates, rinsed twice with PBS, and then the 35 mm plates containing the coverslips were placed into 100 mm plates prefilled with a small volume of sterilized water. Dissociated hEMSCPCs (5 × 10^5 cells/mL × 2 ml of special medium) were then added to the 35 mm plates, followed by incubation for 2–3 days at 36.8 ± 0.2 °C under 5% CO\textsubscript{2} and 100% humidity. During this incubation, the medium was replaced as required based on the degree of acidification (yellowing).

Coverslips with adherent fusiform cells were gently rinsed three times in PBS preheated to 36.8 ± 0.2 °C. Coverslips used for immunohistochemical DB staining were rinsed in 3% hydrogen peroxide, 3% methyl alcohol, and 1% sodium carbonate for 30 minutes, washed in PBS, and then treated with 0.1% triton-X-100 in PBS for 20 minutes. The coverslips were rinsed three times in fresh PBS, dried, and then incubated in the appropriate primary antibody for 1 hour at 37 °C. Fixed and immuno-stained cells on coverslips were rinsed in PBS (×3, 3 min per rinse). Immunostaining was visualized using a commercial kit (Thermoscientific, UK). Solution A (intensifier) was added drop by drop, and cells incubated at 37 °C for 15 min, followed by rinsing in PBS (×3, 3 min per rinse).

For immunocytochemistry, horse radish peroxidase (HRP)-conjugated Anti Ms/Rb IgG was then added and cells incubated for 20 min at 37 °C, followed by rinsing in PBS (×3, 3 min per rinse). Finally, the chromogen DAB was added for 10 min at room temperature under a microscope. Coverslips were rinsed with tap water to terminate the reaction, and sections were dehydrated in a series of alcohol baths (70%, 80%, 90%, and 100% alcohol for 5 min each), and then in 3% hydrogen peroxide for 10 min. Coverslips were then incubated in tap water, left to dry, and then mounted in mounting medium (Thermoscientific, UK), and observed and photographed under a regular optical microscope (Zeiss, Germany). For CD90, CD73, CD105 (Santa Cruz, USA), HLA-DR or HLA-A1 (Invitrogen, USA), immunostaining, coverslips were rinsed with PBS, fixed for 1 min using 3% formaldehyde plus glacial acetic acid pre-cooled to 0 °C, and immediately incubated with an FITC-labeled antibody according to the protocol provided by the manufacturer. Coverslips were then dehydrated at 70% alcohol, and observed and photographed under a laser confocal microscope (Zeiss, Germany) using filter sets for FITC (405 nm excitation, 461 nm emission) and FITC (488 nm excitation, 525 nm emission).

Flow cytometry. After passage, cells were incubated in culture flasks for 40–48 hours and then deplated/dispersed with 0.25% trypsin–0.02% EDTA into a single cell suspension. Following two rinses in PBS, cells were re-suspended in a small volume of PBS and the suspension transferred to 1.5 mL microcentrifuge tubes. The specific flow cytometry protocol depended on whether direct or indirect labeling was used. Monoclonal mouse anti-human CD73, CD34, and HLA-DR antibodies (BD, USA), monoclonal mouse anti-human CD45, CD3, CD19, and HLA-1 antibodies (Becton-Dickinson, USA), and goat anti-human anti-helena antibodies (Invitrogen, USA), were used with appropriate isotype controls (PE-, PerC-, FITC-IgG1-, and FITC-IgG2-isotype controls, all provided by the corresponding antibody supplier), were used for direct immunolabeling of the corresponding proteins. Monoclonal mouse anti-human vitrein (Ancab, USA) and β-III-tubulin (Millipore, USA), and polyclonal rabbit anti-human nestin and GFAP antibodies (Ancab, USA) were used for indirect immunolabeling of the corresponding proteins. The secondary antibodies were goat anti-mouse-PE and goat anti-rabbit-FITC (Southern Biotech, USA). A cell fixation and permeabilization kit was used to label intracellular antigens (Invitrogen, USA). All procedures were conducted according to the manufacturer’s protocols. Cells were subsequently stained only with the secondary antibody were used as isotype controls for indirectly labeling experiments. After treatment, immunolabeling was detected by flow cytometry (FACScaria, BD, USA) and the data analyzed by FCS Express V3. Values for isotype controls were within 0%–1%.

Construction of chimeras. Human EMSCPCs, frozen in liquid N\textsubscript{2} at P10–P13 in 10% DMSO, were thawed in a 35–37 °C water bath, suspended in DMEM containing 10% FBS, and centrifuged at 1,200 rpm for 5 min. The supernatant was removed and the cell pellet re-suspended in 0.5 mL serum-free DMEM, incubated at 6–8 °C for 10 min,
and then injected into mouse blastocoeles under a light microscope. Each mouse blastocoele was injected with 6–8 cells. Injected mouse embryos were incubated overnight at 36.8 ± 0.2 °C under 5% CO2 and 100% humidity. On the second day, well-developed embryos were transferred into the uteri of 2.5-day pseudo-pregnant female mice. In 18 ± 1 days, pups were born. Some pseudo-pregnant mice could not be impregnated, would miscarriage, or give birth to deformed pups that would die soon after birth. Among pups surviving for more than one month, only females were used for examination of hEMSCPCs survival, differentiation, and integration into host tissue.

1. Ledford, H. Hidden toll of embryo ethics war. Nature 471, 279 (2011).
2. Lo, B. & Parham, L. Ethical issues in stem cell research. Am. J. Bioethics 10, 204–213 (2009).
3. Pera, M. F. Stem cells: The dark side of induced pluripotency. Nature 471, 46–47 (2011).
4. Dolgin, E. Flaw in induced stem-cell model. Nature 471, 46–47 (2011).
5. Hussein, S. M. et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471, 58–62 (2011).
6. Gore, A. et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471, 63–67 (2011).
7. Lister, R. et al. Hotspots of aberrant epigenetic reprogramming in human induced pluripotent stem cells. Nature 471, 68–73 (2011).
8. Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285–290 (2010).
9. Laurent, L. C. et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8, 106–118 (2011).
10. Mayshar, Y. et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7, 521–531 (2010).
11. Finney, B. et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nature Medicine 6(11), 1278–1281 (2000).
12. Parekkadan, B. & Milwid, J. M. Mesenchymal stem cells as therapeutics. Cell Stem Cell 20, 301–518 (2010).
13. Shi, Y. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Research 20, 210–518 (2010).
14. Li, J. et al. Enrichment of putative human epithelial mesenchymal stem cells based on cell size and collagen type IV adhesiveness. Cell Research 18, 360–371 (2008).
15. Keyoung, H. M. et al. High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain. Nature Biotechnology 19, 843–850 (2001).
16. Estes, B. T. et al. Isolation of adipose-derived stem cells and their induction to a chondrogenic phenotype. Nature Protocols 5(7), 1294–1311 (2010).
17. Auenflers, C. et al. Adipose-derived stem cells (ASCs) as a source of endothelial cells in the reconstruction of endothelialized skin equivalents. J Tissue Eng Regen Med. 6, 512–518 (2012).
18. Brown, S. G., Harman, R. J. & Black, L. L. Adipose-derived stem cell therapy for severe muscle tears in working German shepherds: Two case reports. Stem Cell Discovery 2, 41–44 (2012).
19. Ramiya, V. K. et al. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature Medicine 6(3), 278–281 (2000).
20. Jiang, F. X. & Morahan, G. Pancreatic stem cells: From possible to probable. Stem Cell Reviews and Reports 8, 647–657 (2012).
21. Seandel, M. et al. Generation of functional multipotent adult stem cells from GPR125- germline progenitors. Nature 449, 346–350 (2007).
22. Conrad, S. et al. Generation of pluripotent stem cells from adult human testis. Nature 456, 344–351 (2008).
23. Gong, S. P. et al. Derivation of histocompatible stem cells from ovarian tissue. J Reprod Dev. 56(5), 481–94 (2010).
24. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells: Implications for tis.

Scientific Reports | 3 : 1933 | DOI: 10.1038/srep01933

Acknowledgements

We are grateful to members of State Key Laboratory of Ophthalmology, Zhong Shan Ophthalmic Center, Sun Yat-sen University for advice. This work was supported by Scientific and Technological Projects of Guangdong Province, China (No.2012B040304009, No.2010B060500006).

Author contributions

B.H. (project design, generation and characterization of hEMSCPCs, and preparation of manuscript), J.G. (project design, members organize and preparation of manuscript), W.L., Y.L. and W.W. (Make up Chimera), J.Y., L.G. and L.L. (PCR of Human SRY, and preparation of manuscript), M.Z. and S.L. (immunocytochemistry), X.H. (FISH of Human Y), X.S. (Epigenetic memory in induced pluripotent stem cells).

Additional information

Supplementary information accompanies this paper at http://www.nature.com/scientificreports

Competing financial interests: The authors declare no competing financial interests.

License: This work is licensed under a Creative Commons Attribution NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/

How to cite this article: Huang, B. et al. Generation of Human Epidermis-Derived Mesenchymal Stem Cell-like Pluripotent Cells (hEMSCPCs). Sci. Rep. 3, 1933; DOI:10.1038/srep01933 (2013).